专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JPH1094393A TARGETING VECTOR FOR PRODUCING PHYSIOLOGICALLY ACTIVE SUBSTANCE 失效
公开(公告)号：JPH1094393A
公开(公告)日：1998-04-14
申请号：JP27136996
申请日：1996-09-20
申请人： CHEMO SERO THERAPEUT RES INST
发明人： MAEDA HIROAKI , NISHIYAMA KIYOTO , IMAMURA TAKAYUKI , MIZUMOTO SEIYA , SOEJIMA KENJI , NAKAMURA KEIKO , IMAGAWA YOSHITAKA
IPC分类号： G01N33/53 , A61K38/00 , A61K38/21 , A61K38/22 , C07H21/04 , C07K14/505 , C07K14/52 , C12N5/00 , C12N5/10 , C12N15/09 , C12P21/02 , C12R1/91
摘要： PROBLEM TO BE SOLVED: To obtain the subject new vector containing a DNA having a foreign expression-regulating region and containing the structural gene of a physiologically active substance at both the ends, useful for substituting an expression-regulating region by the foreign expression-regulating region, and giving a human liver cell capable of stably and higher producing the physiologically active substance. SOLUTION: In this new homologous recombination targeting vector for substituting an expression-regulating region for a physiologically active substance by a foreign expression-regulating region by a homologous recombination method, a DNA containing the foreign expression-regulating region, and a DNA having homology for a part of the gene sequence of the 5'-upstream region of a structural gene for the physiologically active substance or the 5'-upstream region containing a part of the 5'-end side of the structural gene are arranged. The targeting vector is useful for producing a human liver cell capable of stably and highly producing the physiologically active substance. The vector is obtained by combining glutathione-S-transferase enhancer with another promotor and subsequently binding the homologous region of a desired physiologically active substance to the 5' and 3'-sides of the combination product.

2. 发明专利

JP2007116983A Method for producing recombinant aprotinin 审中-公开
标题翻译：生产重组蛋白的方法
公开(公告)号：JP2007116983A
公开(公告)日：2007-05-17
申请号：JP2005313509
申请日：2005-10-27
申请人： Chemo Sero Therapeut Res Inst , 財団法人化学及血清療法研究所
发明人： YONEDA AKIHIRO , NAKATAKE HIROSHI , IMAMURA TAKAYUKI , NOZAKI CHIKAHIDE
IPC分类号： C12N15/09 , C12N1/19 , C12P21/02
摘要： PROBLEM TO BE SOLVED: To provide a kind of yeast that produces a recombinant aprotinin having a natural-type N-terminal side amino acid sequence, and to provide a method for preparing the yeast. SOLUTION: An expression cassette includes a nucleic acid fragment where a pre-α-conjugate factor signal sequence, an aprotinin structural gene and an ADHI terminator are joined downstream of a PRB1 promoter, and produces the recombinant aprotinin. The yeast produces the recombinant aprotinin and is incorporated with the expression cassette, and a method for producing the recombinant aprotinin uses the yeast. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供一种产生具有天然型N-末端侧氨基酸序列的重组抑肽酶的酵母，并提供制备酵母的方法。解决方案：表达盒包括其中pre-α共轭因子信号序列，抑肽酶结构基因和ADHI终止子连接在PRB1启动子下游的核酸片段，并产生重组抑肽酶。酵母产生重组抑肽酶，并与表达盒并入，并且重组抑肽酶的制备方法使用酵母。版权所有（C）2007，JPO＆INPIT

3. 发明专利

JP2005074079A Hemostatic material 审中-公开
标题翻译： HEMOSTATIC MATERIAL
公开(公告)号：JP2005074079A
公开(公告)日：2005-03-24
申请号：JP2003310129
申请日：2003-09-02
申请人： Chemo Sero Therapeut Res Inst , Masao Tanihara , 正夫谷原 , 財団法人化学及血清療法研究所
发明人： TANIHARA MASAO , KINOSHITA HISAO , IMAMURA TAKAYUKI , NOZAKI CHIKAHIDE
IPC分类号： A61K47/34 , A61K38/48 , A61K47/36 , A61K47/42 , A61L15/44 , A61P7/04
摘要： PROBLEM TO BE SOLVED: To provide a hemostatic material which is excellent in a hemostatic effect, in vivo decomposing and absorbing property, uniformity in quality, and stability, and which reduces the risk of mixing an animal-derived pathogen.
SOLUTION: This hemostatic material contains thrombin and a synthetic polypeptide which can form a tri-helix structure. The molecular weight of the polypeptide can indicate a peak in the range of 5×10
4 -100×10
4 . The polypeptide may contain a peptide unit expressed at least by the formula, Pro-X-Gly (X indicates Pro or Hyp (hydroxyproline) in the formula). Thrombin can be a recombinant. The rate of thrombin can be a degree of 0.1-500 unit (U) with respect to the polypeptide in the hemostatic material. A binder component having in vivo decomposing and absorbing property can be contained in the hemostatic material. The material can be formed on a base material.
COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题：提供止血效果优异，体内分解吸收性，质量均匀性和稳定性优异的止血材料，降低动物来源病原体的混合风险。解决方案：该止血材料含有可以形成三螺旋结构的凝血酶和合成多肽。多肽的分子量可以表示在5×10 -4 / SP> -100×10 4 的范围内的峰。多肽可以含有至少由下式表示的肽单元，Pro-X-Gly（X表示式中的Pro或Hyp（羟基脯氨酸））。凝血酶可以是重组体。关于止血材料中的多肽，凝血酶的比例可以是0.1-500单位（U）的程度。在止血材料中可以含有具有体内分解吸收性的粘合剂成分。该材料可以形成在基材上。版权所有（C）2005，JPO＆NCIPI

4. 发明专利

JP2002306163A METHOD OF PREPARING GENE-RECOMBINANT HUMAN THROMBIN USING ESCHERICHIA COIL AS HOST 失效
公开(公告)号：JP2002306163A
公开(公告)日：2002-10-22
申请号：JP2001113253
申请日：2001-04-11
申请人： CHEMO SERO THERAPEUT RES INST
发明人： SOEJIMA KENJI , YONEMURA HIROSHI , NAKATAKE HIROSHI , IMAMURA TAKAYUKI , NOZAKI CHIKAHIDE
IPC分类号： C12N15/09 , C12N1/21 , C12N9/74 , C12R1/19
摘要： PROBLEM TO BE SOLVED: To provide a method of preparing gene-recombinant human thrombin by use of Escherichia coli as a host and improve the efficiency of the steps of the recovery of the inclusion bodies of human prothrombin as an expression product of Escherichia coli, the solubilization thereof and the rewinding. SOLUTION: The steps of the inclusion body recovery, the solubilization of the inclusion body and the rewinding are carried out by the following operations: (1) the inclusion bodies are dispersed in the solubilization buffer; (2) the solubilization by crushing with ultrasonic wave or physical shearing force; and (3) dilution into refolding buffer solution. Desired recombinant thrombin preparation is given that can substitute the conventional thrombin preparations originating from bovine blood or human plasma.

5. 发明专利

JPS6358260A METHOD FOR MEASURING IGM TYPE ANTIBODY 失效
公开(公告)号：JPS6358260A
公开(公告)日：1988-03-14
申请号：JP20396386
申请日：1986-08-29
申请人： CHEMO SERO THERAPEUT RES INST
发明人： YAMAUCHI YOSHIHIRO , IMAMURA TAKAYUKI , NAKAJIMA TOSHIHIRO , TSUJI ICHIRO , UNOKI MASANORI
IPC分类号： G01N33/577 , C12N15/00 , C12N15/02 , C12P21/00 , C12P21/08 , G01N33/53 , G01N33/576
摘要： PURPOSE:To enable exact and rapid measurement by bringing an anti-IgM antibody fixed to a solid phase and specimen into reaction to form an anti-IgM antibody-IgM.antibody complex, and bringing a labeling monoclonal antibody into reaction simultaneously with the complex. CONSTITUTION:For example, 10mul specimen diluted 50 times with a phsyological salt soln. and 200mul specimen diluting liquid are put into a test tube and a piece of a previously prepd. anti-human IgM antibody coated bead is added thereto. The tube is shaken for 1hr at 37 deg.C to absorb the IgM antibody in the specimen to the bead. After the soln. is sucked away, the test tube is cleaned 3 times with distilled water and 200mul HBc antigen liquid is added thereto; further the tube is shaken for 2hr at 37 deg.C. The soln. is again sucked away after the reaction and the test tube is cleaned 3 times with the distilled water; thereafter, the solid phase bead is retransferred into the test tube and 1ml o-phenylene diamine 2HCl soln. is added thereto and the tube is rested for 30min at 37 deg.C in a dark place. The reaction is then stopped by adding 1ml 2N aq. sulfuric acid soln. thereto. The absorbancy at 492nm of the respective test tubes is measured by a spectrophotometer. The measurement time is thereby shortened to a greater extent.

6. 发明专利

JPS61209357A MEASUREMENT OF HBC ANTIBODY 失效
公开(公告)号：JPS61209357A
公开(公告)日：1986-09-17
申请号：JP5167885
申请日：1985-03-14
申请人： CHEMO SERO THERAPEUT RES INST
发明人： SUGAWARA KEISHIN , IMAMURA TAKAYUKI , FUJITA HARUO , YAGAMI KAZUHIDE
IPC分类号： A61K39/29 , C07K14/02 , C12N15/00 , C12N15/09 , G01N30/88 , G01N33/531 , G01N33/576 , G01N33/577
摘要： PURPOSE:To make it possible to measure a HBc antibody with high sensitivity, by utilizing recominant DNA technique to develop a HBc antigen in yeast and using the yeast producing HBc antigen. CONSTITUTION:A yeast producing HBc antigen is produced and accumulated by culturing a recombinant, that is, a yeast fungus, of which the character is transformed by recombinant DNA technique so as to produce a HBc antigen, in a proper culture medium. Yeast cells are centrifugally separated from the culture medium to be ground in a buffer solution and applied to low speed centrifugal separation to obtain a HBc antigen stock material. An acid is added to this stock material to transfer the pH thereof to an acidic side and lipids or impurity protein are removed as a precipitate. Thereafter, ion exchange chromatography and density gradient centrifugal separation are successively performed to make it possible to highly purify the HBc antigen. The measurement of a HBc antibody is enabled by a PHA method, an EIA method or a RIA method using thus obtained HBc antigen.

7. 发明专利

JP2010124931A Method for manufacturing package of freeze-dried medicine 审中-公开
标题翻译：冷冻干燥药物包装方法
公开(公告)号：JP2010124931A
公开(公告)日：2010-06-10
申请号：JP2008300741
申请日：2008-11-26
申请人： Chemo Sero Therapeut Res Inst , Kanae Co Ltd , 株式会社カナエ , 財団法人化学及血清療法研究所
发明人： IMAMURA TAKAYUKI , OWAKI HITOMI , MAEDA HIROAKI , AKIMURA YASUNORI
IPC分类号： A61J3/00 , A61J1/03 , F26B5/06
CPC分类号： F26B5/06
摘要： PROBLEM TO BE SOLVED: To provide a method for manufacturing the sterile package of a freeze-dried medicine without requiring a large amount of equipment investment to keep sterile property nor having the risk of deformation or deactivation when the medicine is protein, etc., concerning the method for manufacturing the package of the freeze-dried medicine with the sterile property kept therein. SOLUTION: The method includes the following processes (1) to (3), i.e., (1) the process for storing the medicine to be freeze-dried in a container under the sterile property, (2) the process for allowing a sealed sheet with bacteria-blocking property and ventilation to be welded onto the peripheral edge of the container with the medicine stored therein under the sterile property, and (3) the process for freeze-drying the container which is sealed after welding the sealed sheet onto the peripheral edge of the container. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：要解决的问题：提供一种用于制造冷冻干燥药物的无菌包装的方法，而不需要大量的设备投资来保持无菌性质，当药物是蛋白质等时，也不具有变形或失活的风险。关于制造具有保存在其中的无菌性质的冷冻干燥药物包装的方法。解决方案：该方法包括以下（1）至（3）的方法，即（1）在无菌性质下将容器中的待冷冻干燥药物储存的方法，（2）允许的方法具有细菌阻隔性的密封片材和通气，其中药物在无菌性质下存储在容器的周边边缘上，以及（3）在将密封片材焊接之后密封的容器的冷冻干燥方法到容器的外围边缘。版权所有（C）2010，JPO＆INPIT

8. 发明专利

JP2010069031A Sheet-like fibrin glue adhesive 审中-公开
标题翻译：类似薄膜胶粘剂
公开(公告)号：JP2010069031A
公开(公告)日：2010-04-02
申请号：JP2008240228
申请日：2008-09-19
申请人： Chemo Sero Therapeut Res Inst , 財団法人化学及血清療法研究所
发明人： IMAMURA TAKAYUKI , YANO KENTARO , TSUGO HITOMI , OWAKI HITOMI , HIRASHIMA MASAKI , MAEDA HIROAKI
IPC分类号： A61L24/00
摘要： PROBLEM TO BE SOLVED: To provide a sheet-like fibrin glue adhesive which is excellent in hemostatic effects and adhesion to tissues. SOLUTION: The sheet-like fibrin glue adhesive comprises a bioabsorbable support to which a fibrinogen is fixed as an active ingredient and a bioabsorbable support to which a thrombin is immobilized as an active ingredient. A nonionic surfactant is added to the fibrinogen-immobilized support, and thereby it gets the excellent hemostatic effects and adhesion to tissues and can adhere to tissues on both faces, so that it can be suitably used for reparation of a great vessel in surgery. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：要解决的问题：提供止血效果和组织粘附性优异的片状纤维蛋白胶粘合剂。解决方案：片状纤维蛋白胶粘剂包括生物可吸收载体，纤维蛋白原作为活性成分固定在其上，凝固酶固定在其上作为活性成分的生物可吸收载体。将非离子表面活性剂加入到纤维蛋白原固定化载体中，从而获得优异的止血效果和对组织的粘附性，并且可以粘附在两个面上的组织上，从而可以适用于手术中大血管的修复。版权所有（C）2010，JPO＆INPIT

9. 发明专利

JP2010063504A Carboxylic acid-containing biomedical tissue adhesive and method of preparing the same 有权
标题翻译：含羧酸的生物医用组织粘合剂及其制备方法
公开(公告)号：JP2010063504A
公开(公告)日：2010-03-25
申请号：JP2008230369
申请日：2008-09-09
申请人： Chemo Sero Therapeut Res Inst , 財団法人化学及血清療法研究所
发明人： SAGA HIDEKI , ARAKI TATSUYA , HAMURO TSUTOMU , KAWAMURA RYOICHI , SOEJIMA KENJI , KAETSU HIROSHI , HIRASHIMA MASAKI , IMAMURA TAKAYUKI
IPC分类号： A61L24/00
摘要： PROBLEM TO BE SOLVED: To provide a carboxylic acid-containing biomedical tissue adhesive and a method of preparing the same. SOLUTION: A biomedical tissue adhesive consists of fibrinogen composition containing carboxylic acid or salt thereof at a rate of 0.05 mmol or more with respect to 40 mg of fibrinogen and a thrombin composition, a biomedical tissue adhesive is formed by applying at least one of the fibrinogen composition or the thrombin composition to a bioabsorbable sheet, and methods of preparing these biomedical tissue adhesives. The carboxylic acid or salt thereof is used by combining one or a plurality of acids selected from a group consisting of acetic acid, glutamic acid, citric acid, tartaric acid, aspartic acid, malic acid, succinic acid and salts thereof. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供含羧酸的生物医学组织粘合剂及其制备方法。解决方案：生物医学组织粘合剂由含有羧酸或其盐的纤维蛋白原组合物组成，相对于40mg纤维蛋白原和凝血酶组合物，其速率为0.05mmol以上，生物医学组织粘合剂通过施用至少一种的纤维蛋白原组合物或凝血酶组合物转化为生物可吸收片材，以及制备这些生物医学组织粘合剂的方法。羧酸或其盐通过组合一种或多种选自乙酸，谷氨酸，柠檬酸，酒石酸，天冬氨酸，苹果酸，琥珀酸及其盐的酸来使用。版权所有（C）2010，JPO＆INPIT

10. 发明专利

JP2009183649A Sheet-like tissue adhesive 有权
标题翻译：类似片状粘合剂
公开(公告)号：JP2009183649A
公开(公告)日：2009-08-20
申请号：JP2008029785
申请日：2008-02-08
申请人： Chemo Sero Therapeut Res Inst , 財団法人化学及血清療法研究所
发明人： HIRASHIMA MASAKI , MATSUYAMA REIKO , IMAMURA TAKAYUKI
IPC分类号： A61L15/44 , A61K9/70 , A61K38/00 , A61K47/34 , A61K47/38 , A61P17/02
摘要： PROBLEM TO BE SOLVED: To provide a novel sheet-like tissue adhesive used for arresting hemorrhage and for closing a tissue during a surgical operation. SOLUTION: The sheet-like tissue adhesive is constituted of a layer containing fibrinogen as the main component, a layer containing thrombin as a main component, and an intermediate layer interposed between both the above layers. The sheet-like tissue adhesive attains substantially excellent tissue adhering effect and blood arresting effect by that gelling speed of the fibrinogen is optimized as the result that the fibrinogen can react with the thrombin after the fibrinogen sufficiently permeates into a tissue adhering site by interposing the intermediate layer comprising a cellulose derivative such as hydroxypropylcellulose. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供一种新颖的片状组织粘合剂，用于在手术过程中阻止出血和闭合组织。解决方案：片状组织粘合剂由含有纤维蛋白原作为主要成分的层，含有凝血酶作为主要成分的层以及介于上述两层之间的中间层构成。片状组织粘合剂通过纤维蛋白原的胶凝速度获得基本上优异的组织粘附效果和止血效果，其结果是纤维蛋白原可以在纤维蛋白原充分渗透到组织粘附位点后与凝血酶反应，通过插入中间体包含纤维素衍生物如羟丙基纤维素的层。版权所有（C）2009，JPO＆INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式